D2B3 develops a pre‑clinical platform that transiently relaxes the blood‑brain barrier to enable targeted delivery of therapeutics to the central nervous system. The technology is designed to be plug‑and‑play, compatible with a wide range of drug molecules and therapeutic classes. This approach aims to improve efficacy for CNS disease treatments by overcoming delivery challenges.
Funding
Funding not disclosed
Founders
Product
Problem
The blood-brain barrier (BBB) restricts the passage of many potentially therapeutic molecules into the central nervous system (CNS), limiting the effectiveness of drugs targeting neurological disorders. This barrier poses a significant challenge in treating CNS diseases, as it prevents adequate drug concentrations from reaching the brain tissue. Current methods for circumventing the BBB are often invasive or lack precise targeting.
Solution
D2B3 develops a technology platform for transiently opening the blood-brain barrier (BBB), enabling enhanced delivery of therapeutic agents to the central nervous system (CNS). Their approach utilizes a proprietary method to temporarily and selectively increase BBB permeability, facilitating the passage of a wide range of drug classes into the brain. This targeted delivery system aims to improve the efficacy of CNS therapeutics by ensuring that drugs reach the affected brain regions at optimal concentrations. By overcoming the limitations of the BBB, D2B3 seeks to provide a non-invasive solution for treating a variety of neurological diseases.
Target Audience
D2B3's primary customers are pharmaceutical and biotechnology companies developing therapeutics for neurological disorders, as well as researchers investigating novel drug delivery methods to the brain.
Features
- Proprietary technology for transient and targeted opening of the blood-brain barrier
- Enhanced delivery of therapeutics to the central nervous system
- Non-invasive approach to bypass the BBB
- Potential application across a range of CNS diseases